From:

Robert Davis [/O=REGENERON/OU=FIRST ADMINISTRATIVE

GROUP/CN=RECIPIENTS/CN=ROBERT.DAVIS]

Sent:

Friday, December 06, 2013 2:24:23 PM

To:

John Calabro; William Daniels

CC: Subject: Robert Krukowski; Cathy Casey RE: report + additional questions

Attachments:

image001.png

John,

It is all verbal.

Thank you,

Bob

Robert C. Davis U.S. | Executive Director & Head of Trade, Reimbursement & Managed Markets REGENERON Pharmaceuticals, Inc. | 777 Old Saw Mill River Road | Tarrytown, NY 10591 Tel: 914.847.7690 | Fax: 914.931-2017 | Cell: 914-282-4007 | Email: robert.davis@regeneron.com 1-855-EYLEA-4U (1-855-395-3248)

REGENERON



















From: John Calabro

Sent: Friday, December 06, 2013 7:26 AM

To: William Daniels

Cc: Robert Davis; Robert Krukowski; Cathy Casey Subject: RE: report + additional questions

Bill:

When she makes a request for additional funding, how does she justify it? Can you send me an example email?

Thanks,

John

From: William Daniels

Sent: Thursday, December 05, 2013 4:48 PM

To: John Calabro

Cc: Robert Davis; Robert Krukowski; Cathy Casey Subject: Re: report + additional questions

John,

No I don't receive any other reports or data

My contact estimates what she needs for the year verbally and then we divide across the year when we can afford it. If

CONFIDENTIAL REG_000143628 she is running low, she calls and indicates what more she needs.

Bil Daniels REGENERON Pharmaceuticals Tel: 914.606.0878

Sent from my iPad

On Dec 5, 2013, at 3:24 PM, "John Calabro" < John.Calabro@regeneron.com > wrote:

Bill-

Can you please respond to the email below?

Thanks,

John

From: John Calabro

Sent: Wednesday, December 04, 2013 8:43 AM

To: William Daniels

Cc: Robert Davis; Robert Krukowski; Cathy Casey **Subject:** re: report + additional questions

Importance: High

Hi Bill:

It turns out the report is attached, for some reason it doesn't show up on the i-phone.

I did forget to confirm a couple of things with you yesterday:

- Do you receive any other reports or data in emails from CDF? If so, please provide
- How does CDF make a request for additional funding? Is it verbal or by email? How do they justify
 it? Please provide any documentation you might have regarding such requests.

Thanks,

John

John P. Calabro, CPA, CIA Executive Director, Internal Audit Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Rd. Tarrytown, NY. 10591 914-847-7986